IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75.” December 10, 2025 Read More »
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer’s Agitation Trial December 9, 2025 Read More »
IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer’s Disease December 2, 2025 Read More »
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer’s and Aging Trends November 25, 2025 Read More »
IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital November 18, 2025 Read More »
USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer’s Disease and Central Nervous System Disorders November 13, 2025 Read More »
IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025 November 10, 2025 Read More »
IGC Pharma Advances to Semi-Finals in the Alzheimer’s Insights AI Prize with “AHA: Agentic Harmonization Assistant” October 22, 2025 Read More »
IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida’s Department of Psychiatry and Behavioral Neurosciences October 14, 2025 Read More »
